Prognostic survival associated with left-sided vs right-sided colon cancer a systematic review and meta-analysis

JAMA Oncology

Volumn 3, Issue 2, 2017, Pages 211-219

  Petrelli, Fausto ^a   Tomasello, Gianluca ^b   Borgonovo, Karen ^a   Ghidini, Michele ^b   Turati, Luca ^a   Dallera, Pierpaolo ^a   Passalacqua, Rodolfo ^b   Sgroi, Giovanni ^a   Barni, Sandro ^a  

^a Oncology Unit   (Italy)

^b CREMONA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85018200927     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.4227     Document Type: Review

References (94)

1. Holleczek B, Rossi S, Domenic A, et al; EUROCARE-5Working Group. On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999-2007-Results from the EUROCARE-5 study. Eur J Cancer. 2015; S0959-8049(15)00704-2.
2. Amri R, Bordeianou LG, Sylla P, Berger DL. Impact of screening colonoscopy on outcomes in colon cancer surgery. JAMA Surg. 2013;148(8):747-754.
3. Saidi HS, Karuri D, Nyaim EO. Correlation of clinical data, anatomical site and disease stage in colorectal cancer. East Afr Med J. 2008;85(6):259-262.
4. Shen H, Yang J, Huang Q, et al. Different treatment strategies and molecular features between right-sided and left-sided colon cancers. World J Gastroenterol. 2015;21(21):6470-6478.
5. Sinicrope FA, MahoneyMR, Smyrk TC, et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol. 2013;31(29):3664-3672.
6. Weiss JM, Pfau PR, O'Connor ES, et al. Mortality by stage for right-versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results-Medicare data. J Clin Oncol. 2011;29(33): 4401-4409.
7. Loupakis F, Yang D, Yau L, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst. 2015;107(3): dju427.
8. Deeks JJ, Dinnes J, D'Amico R, et al; International Stroke Trial Collaborative Group; European Carotid Surgery Trial Collaborative Group. Evaluating non-randomised intervention studies. Health Technol Assess. 2003;7(27):iii-x, 1-173.
9. Wells G, Shea B, O'Connell D. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomizes studies inmeta-analyses. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp. Accessed December 29, 2015.
10. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088-1101.
11. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634.
12. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455-463.
13. Ahmadi O, Stringer MD, Black MA,McCall JL. Clinico-pathological factors influencing lymph node yield in colorectal cancer and impact on survival: analysis of New Zealand Cancer Registry data. J Surg Oncol. 2015;111(4):451-458.
14. Al-Mulla F, Hagan S, Behbehani AI, et al. Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. J Clin Oncol. 2006;24(36):5672-5679.
15. André T, de Gramont A, Vernerey D, et al. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. J Clin Oncol. 2015;33(35):4176-4187.
16. Bhangu A, Kiran RP, Slesser A, Fitzgerald JE, Brown G, Tekkis P. Survival after resection of colorectal cancer based on anatomical segment of involvement. Ann Surg Oncol. 2013;20(13):4161-4168.
17. Boisen MK, Johansen JS, Dehlendorff C, et al. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Ann Oncol. 2013;24(10):2554-2559.
18. Brulé SY, Jonker DJ, Karapetis CS, et al. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer. 2015;51(11): 1405-1414.
19. Budde CN, Tsikitis VL, Deveney KE, Diggs BS, Lu KC, Herzig DO. Increasing the number of lymph nodes examined after colectomy does not improve colon cancer staging. J Am Coll Surg. 2014;218(5): 1004-1011.
20. Chafai N, Chan CL, Bokey EL, Dent OF, Sinclair G, Chapuis PH. What factors influence survival in patients with unresected synchronous liver metastases after resection of colorectal cancer? Colorectal Dis. 2005;7(2):176-181.
21. Cohen SA,Wu C, YuM, et al. Evaluation of CpG island methylator phenotype as a biomarker in colorectal cancer treated with adjuvant oxaliplatin. Clin Colorectal Cancer. 2016;15(2):164-169.
22. Cremolini C, Di Bartolomeo M, Amatu A, et al. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Ann Oncol. 2015;26 (10):2092-2097.
23. Crosara TeixeiraM, Marques DF, Ferrari AC, et al. The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4. Clin Colorectal Cancer. 2015;14(1):52-57.
24. Fariña-Sarasqueta A, van Lijnschoten G, Moerland E, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol. 2010;21(12):2396-2402.
25. Ferrand F, Malka D, Bourredjem A, et al. Impact of primary tumour resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy: results from the multicenter, randomised trial Fédération Francophone de Cancérologie Digestive 9601. Eur J Cancer. 2013;49(1):90-97.
26. George S, Primrose J, Talbot R, et al;Wessex Colorectal Cancer AuditWorking Group. Will Rogers revisited: prospective observational study of survival of 3592 patients with colorectal cancer according to number of nodes examined by pathologists. Br J Cancer. 2006;95(7):841-847.
27. Gilardoni E, Bernasconi DP, Poli S, et al. Surveillance for early stages of colon cancer: potentials for optimizing follow-up protocols.World J Surg Oncol. 2015;13:260.
28. Gleisner AL, Mogal H, Dodson R, et al. Nodal status, number of lymph nodes examined, and lymph node ratio: what defines prognosis after resection of colon adenocarcinoma? J AmColl Surg. 2013;217(6):1090-1100.
29. Hawk NN, Long TE, Imam MH, et al. Clinicopathologic Features and Outcome of Young Adults With Stage IV Colorectal Cancer. Am J Clin Oncol. 2015;38(6):543-549.
30. Horst D, Kriegl L, Engel J, Jung A, Kirchner T. CD133 and nuclear beta-catenin: the marker combination to detect high risk cases of low stage colorectal cancer. Eur J Cancer. 2009;45(11):2034-2040.
31. Ishihara S, Nishikawa T, Tanaka T, et al. Prognostic impact of tumor location in stage IV colon cancer: a propensity score analysis in a multicenter study. Int J Surg. 2014;12(9):925-930.
32. Jeong DH, Kim WR, Min BS, Kim YW, Song MK, Kim NK. Validation of a quantitative 12-multigene expression assay (Oncotype DX(®) Colon Cancer Assay) in Korean patients with stage II colon cancer: implication of ethnic differences contributing to differences in gene expression. Onco Targets Ther. 2015;8:3817-3825.
33. Jess P, Hansen IO, Gamborg M, Jess T; Danish Colorectal Cancer Group. A nationwide Danish cohort study challenging the categorisation into right-sided and left-sided colon cancer. BMJ Open. 2013;3(5):e002608.
34. Johnson PM, Porter GA, Ricciardi R, Baxter NN. Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer. J Clin Oncol. 2006;24(22):3570-3575.
35. Kalady MF, Dejulius KL, Sanchez JA, et al. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon Rectum. 2012;55(2):128-133.
36. Katkoori VR, Shanmugam C, Jia X, et al. Prognostic significance and gene expression profiles of p53 mutations in microsatellite-stable stage III colorectal adenocarcinomas. PLoS One. 2012;7(1):e30020.
37. Katoh H, Yamashita K,Wang G, Sato T, Nakamura T,Watanabe M. Prognostic significance of preoperative bowel obstruction in stage III colorectal cancer. Ann Surg Oncol. 2011;18(9):2432-2441.
38. Koo JH, Jalaludin B,Wong SK, Kneebone A, Connor SJ, Leong RW. Improved survival in young women with colorectal cancer. Am J Gastroenterol. 2008;103(6):1488-1495.
39. Lanza G, Gafà R, Santini A, Maestri I, Guerzoni L, Cavazzini L. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol. 2006;24(15):2359-2367.
40. Le H, Ziogas A, Taylor TH, Lipkin SM, Zell JA. Survival of distinct Asian groups among colorectal cancer cases in California. Cancer. 2009;115(2):259-270.
41. Lee I, Baek S-H, Kim H, et al. Survival analysis for colon subsite and rectal cancers: experience from a single surgeon. Korean J Clin Oncol. 2015;11: 114-119.
42. Liang JT, Huang KC, Cheng YM, et al. P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. Int J Cancer. 2002;97(4): 451-457.
43. Lykke J, Roikjaer O, Jess P; Danish Colorectal Cancer Group. The relation between lymph node status and survival in Stage I-III colon cancer: results from a prospective nationwide cohort study. Colorectal Dis. 2013;15(5):559-565.
44. Magnusson C, MezhybovskaM, Lörinc E, Fernebro E, NilbertM, Sjölander A. Low expression of CysLT1R and high expression of CysLT2R mediate good prognosis in colorectal cancer. Eur J Cancer. 2010;46(4):826-835.
45. Meguid RA, Slidell MB,Wolfgang CL, Chang DC, Ahuja N. Is there a difference in survival between right-versus left-sided colon cancers? Ann Surg Oncol. 2008;15(9):2388-2394.
46. Mekenkamp LJ, Heesterbeek KJ, Koopman M, et al. Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. Eur J Cancer. 2012;48 (4):501-509.
47. Merok MA, Ahlquist T, Røyrvik EC, et al. Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series. Ann Oncol. 2013;24(5):1274-1282.
48. Miyamoto Y, Baba Y, Sakamoto Y, et al. Negative Impact of Skeletal Muscle Loss after Systemic Chemotherapy in Patients with Unresectable Colorectal Cancer. PLoS One. 2015;10 (6):e0129742.
49. Modest DP, Schulz C, vonWeikersthal LF, et al. Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment). Anticancer Drugs. 2014;25(2):212-218.
50. Moritani K, Hasegawa H, Okabayashi K, Ishii Y, Endo T, Kitagawa Y. Difference in the recurrence rate between right-and left-sided colon cancer: a 17-year experience at a single institution. Surg Today. 2014;44(9):1685-1691.
51. Deschoolmeester V, Van Damme N, BaayM, et al. Microsatellite instability in sporadic colon carcinomas has no independent prognostic value in a Belgian study population. Eur J Cancer. 2008;44 (15):2288-2295.
52. Mulder TP, Verspaget HW, Sier CF, et al. Glutathione S-transferase pi in colorectal tumors is predictive for overall survival. Cancer Res. 1995;55 (12):2696-2702.
53. Negri FV,Wotherspoon A, Cunningham D, Norman AR, Chong G, Ross PJ. Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Ann Oncol. 2005;16(8):1305-1310.
54. Nitsche U, Zimmermann A, Späth C, et al. Mucinous and signet-ring cell colorectal cancers differ from classical adenocarcinomas in tumor biology and prognosis. Ann Surg. 2013;258(5):775-782.
55. Norén A, Eriksson HG, Olsson LI. Selection for surgery and survival of synchronous colorectal liver metastases; a nationwide study. Eur J Cancer. 2016;53:105-114.
56. Ogura T, Kakuta M, Yatsuoka T, et al. Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations. Oncol Rep. 2014;32(1):50-56.
57. Oh BY, Huh JW, Park YA, et al. Prognostic factors in sporadic colon cancer with high-level microsatellite instability. Surgery. 2016;159(5):1372-1381.
58. Oue N, Anami K, Schetter AJ, et al. High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer. Int J Cancer. 2014; 134(8):1926-1934.
59. Paquet ER, Cui J, Davidson D, et al. A 12-gene signature to distinguish colon cancer patients with better clinical outcome following treatment with 5-fluorouracil or FOLFIRI. J Pathol Clin Res. 2015;1 (3):160-172.
60. Park JH, Kim TY, Lee KH, et al. The beneficial effect of palliative resection in metastatic colorectal cancer. Br J Cancer. 2013;108(7):1425-1431.
61. Pectasides D, Karavasilis V, Papaxoinis G, et al. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer. BMC Cancer. 2015;15:384-395.
62. Peeples C, Shellnut J,Wasvary H, Riggs T, Sacksner J. Predictive factors affecting survival in stage II colorectal cancer: is lymph node harvesting relevant? Dis Colon Rectum. 2010;53(11):1517-1523.
63. Pentheroudakis G, Raptou G, Kotoula V, et al. Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trial. PLoS One. 2015;10(5):e0124612.
64. Price TJ, Beeke C, Ullah S, et al. Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease? Cancer. 2015; 121(6):830-835.
65. Renfro LA, Grothey A, Xue Y, et al; Adjuvant Colon Cancer Endpoints (ACCENT) Group. ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer. J Natl Cancer Inst. 2014;106(12):dju333.
66. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010;28(3):466-474.
67. Sinicrope FA, Foster NR, Yoon HH, et al. Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials. J Clin Oncol. 2012;30(4):406-412.
68. Suttie SA, Shaikh I, Mullen R, Amin AI, Daniel T, Yalamarthi S. Outcome of right-and left-sided colonic and rectal cancer following surgical resection. Colorectal Dis. 2011;13(8):884-889.
69. Tarantino I,Warschkow R,Worni M, et al. Prognostic Relevance of Palliative Primary Tumor Removal in 37,793Metastatic Colorectal Cancer Patients: A Population-Based, Propensity Score-Adjusted Trend Analysis. Ann Surg. 2015;262 (1):112-120.
70. van Steenbergen LN, Lemmens VE, Rutten HJ, Wymenga AN, Nortier JW, Janssen-Heijnen ML. Increased adjuvant treatment and improved survival in elderly stage III colon cancer patients in The Netherlands. Ann Oncol. 2012;23(11):2805-2811.
71. Wallace K, Hill EG, Lewin DN, et al. Racial disparities in advanced-stage colorectal cancer survival. Cancer Causes Control. 2013;24(3):463-471.
72. Wang R,WangMJ, Ping J. Clinicopathological Features and Survival Outcomes of Colorectal Cancer in Young Versus Elderly: A Population-Based Cohort Study of SEER 9 Registries Data (1988-2011). Medicine (Baltimore). 2015;94(35): e1402.
73. Ward RL, Cheong K, Ku SL, Meagher A, O'Connor T, Hawkins NJ. Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J Clin Oncol. 2003;21(20): 3729-3736.
74. Wray CM, Ziogas A, HinojosaMW, Le H, Stamos MJ, Zell JA. Tumor subsite location within the colon is prognostic for survival after colon cancer diagnosis. Dis Colon Rectum. 2009;52(8):1359-1366.
75. Schrag D,Weng S, Brooks G, Meyerhardt JA, Venook AP. The relationship between primary tumor sidedness and prognosis in colorectal cancer. J Clin Oncol. 2016;34 (suppl abstr, 3505).
76. Venook AP, Niedzwiecki D, Innocenti F, et al. Impact of primary (1) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2016;34(suppl, abstr 3504).
77. Gill SR, Pop M, Deboy RT, et al. Metagenomic analysis of the human distal gut microbiome. Science. 2006;312(5778):1355-1359.
78. Kirby JA, Bone M, Robertson H, Hudson M, Jones DE. The number of intraepithelial T cells decreases from ascending colon to rectum. J Clin Pathol. 2003;56(2):158.
79. Lowichik A,Weinberg AG. A quantitative evaluation of mucosal eosinophils in the pediatric gastrointestinal tract. Mod Pathol. 1996;9(2):110-114.
80. SelbyWS, Janossy G, Jewell DP. Immunohistological characterisation of intraepithelial lymphocytes of the human gastrointestinal tract. Gut. 1981;22(3):169-176.
81. Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117(20): 4623-4632.
82. Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med. 1990;113(10): 779-788.
83. Distler P, Holt PR. Are right-and left-sided colon neoplasms distinct tumors? Dig Dis. 1997;15 (4-5):302-311.
84. Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 2011;29(10):1261-1270.
85. Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer. 2002;101(5):403-408.
86. Breivik J, Lothe RA, Meling GI, Rognum TO, Børresen-Dale AL, Gaudernack G. Different genetic pathways to proximal and distal colorectal cancer influenced by sex-related factors. Int J Cancer. 1997; 74(6):664-669.
87. Benedix F, Schmidt U, Mroczkowski P, Gastinger I, Lippert H, Kube R; Study Group "Colon/Rectum Carcinoma (Primary Tumor)". Colon carcinoma-classification into right and left sided cancer or according to colonic subsite?-analysis of 29,568 patients. Eur J Surg Oncol. 2011;37(2):134-139.
88. HohenbergerW,Weber K, Matzel K, Papadopoulos T, Merkel S. Standardized surgery for colonic cancer: complete mesocolic excision and central ligation-technical notes and outcome. Colorectal Dis. 2009;11(4):354-364.
89. Bertelsen CA, Neuenschwander AU, Jansen JE, et al; Danish Colorectal Cancer Group. Disease-free survival after complete mesocolic excision compared with conventional colon cancer surgery: a retrospective, population-based study. Lancet Oncol. 2015;16(2):161-168.
90. Søndenaa K, Quirke P, HohenbergerW, et al. The rationale behind complete mesocolic excision (CME) and a central vascular ligation for colon cancer in open and laparoscopic surgery: proceedings of a consensus conference. Int J Colorectal Dis. 2014;29(4):419-428.
91. Heinemann V, Modest DP, Fischer vonWeikersthal L. Gender and tumor location as predictors for efficacy: influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial. J Clin Oncol. 2014;32:5s (suppl abstr, 3600).
92. Lee MS, Overman MJ, Maru DM. Association of CpG island methylator phenotype (CIMP) with inferior progression-free survival with anti-EGFR monoclonal antibody therapy inmetastatic colorectal cancer. J Clin Oncol. 2014;32:5s(suppl abstr, 3633).
93. Pietrantonio F, Petrelli F, Coinu A, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: ameta-analysis. Eur J Cancer. 2015;51(5):587-594.
94. Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371 (17):1609-1618.